533 related articles for article (PubMed ID: 34358100)
1. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development.
Hammood M; Craig AW; Leyton JV
Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358100
[TBL] [Abstract][Full Text] [Related]
2. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
Ma H; Sawas A
Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
[TBL] [Abstract][Full Text] [Related]
3. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates.
Mahalingaiah PK; Ciurlionis R; Durbin KR; Yeager RL; Philip BK; Bawa B; Mantena SR; Enright BP; Liguori MJ; Van Vleet TR
Pharmacol Ther; 2019 Aug; 200():110-125. PubMed ID: 31028836
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
[TBL] [Abstract][Full Text] [Related]
5. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
[TBL] [Abstract][Full Text] [Related]
6. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
7. Acquired Resistance to Antibody-Drug Conjugates.
Collins DM; Bossenmaier B; Kollmorgen G; Niederfellner G
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30897808
[TBL] [Abstract][Full Text] [Related]
8. Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.
Zhang X; Huang AC; Chen F; Chen H; Li L; Kong N; Luo W; Fang J
Antib Ther; 2022 Jan; 5(1):18-29. PubMed ID: 35146330
[TBL] [Abstract][Full Text] [Related]
9. Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates.
DeVay RM; Delaria K; Zhu G; Holz C; Foletti D; Sutton J; Bolton G; Dushin R; Bee C; Pons J; Rajpal A; Liang H; Shelton D; Liu SH; Strop P
Bioconjug Chem; 2017 Apr; 28(4):1102-1114. PubMed ID: 28151644
[TBL] [Abstract][Full Text] [Related]
10. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.
Kalim M; Chen J; Wang S; Lin C; Ullah S; Liang K; Ding Q; Chen S; Zhan J
Drug Des Devel Ther; 2017; 11():2265-2276. PubMed ID: 28814834
[TBL] [Abstract][Full Text] [Related]
11. Introduction to Antibody-Drug Conjugates.
Pettinato MC
Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
[TBL] [Abstract][Full Text] [Related]
12. Advances and Limitations of Antibody Drug Conjugates for Cancer.
Mckertish CM; Kayser V
Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440076
[TBL] [Abstract][Full Text] [Related]
13. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.
Nguyen TD; Bordeau BM; Balthasar JP
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765668
[TBL] [Abstract][Full Text] [Related]
15. Fate of Antibody-Drug Conjugates in Cancer Cells.
Chalouni C; Doll S
J Exp Clin Cancer Res; 2018 Feb; 37(1):20. PubMed ID: 29409507
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic Modeling of Antibody-Drug Conjugate Internalization at the Cellular Level Reveals Inefficient Processing Steps.
Durbin KR; Phipps C; Liao X
Mol Cancer Ther; 2018 Jun; 17(6):1341-1351. PubMed ID: 29592884
[TBL] [Abstract][Full Text] [Related]
17. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
18. A Bispecific METxMET Antibody-Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes.
Perez Bay AE; Faulkner D; DaSilva JO; Young TM; Yang K; Giurleo JT; Ma D; Delfino FJ; Olson WC; Thurston G; Daly C; Andreev J
Mol Cancer Ther; 2023 Mar; 22(3):357-370. PubMed ID: 36861363
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
20. The Analysis of Key Factors Related to ADCs Structural Design.
Tang H; Liu Y; Yu Z; Sun M; Lin L; Liu W; Han Q; Wei M; Jin Y
Front Pharmacol; 2019; 10():373. PubMed ID: 31068807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
